表紙
市場調查報告書

上呼吸道感染治療的全球市場:2020年∼2024年

Global Upper Respiratory Tract Infection Treatment Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 934843
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
上呼吸道感染治療的全球市場:2020年∼2024年 Global Upper Respiratory Tract Infection Treatment Market 2020-2024
出版日期: 2020年05月02日內容資訊: 英文 120 Pages
簡介

全球上呼吸道感染治療市場在2020年∼2024年的預測期間內,預計將以3%的年複合成長率增長,達到17億9,000萬美元的規模。市場成長的主要因素有上呼吸道感染的發病率和流行率上升,藥品管道良好以及對非處方藥的需求增加。

本報告提供全球上呼吸道感染治療市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

各類型市場區隔

  • 市場區隔
  • 各類型比較:市場規模·預測(2019年∼2024年)
  • 抗生素
  • 非甾體抗炎藥和鼻充血藥
  • 其他
  • 各類型的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模·預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 各地區市場機會
  • 交易量的成長要素-需求主導型成長
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 形勢的創新
  • 競爭模式

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AstraZeneca Plc
  • CSL Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

附錄

目錄
Product Code: IRTNTR43396

Technavio has been monitoring the upper respiratory tract infection treatment market and it is poised to grow by $ 1.79 billion during 2020-2024 progressing at a CAGR of 3% during the forecast period. Our reports on upper respiratory tract infection treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising incidence and prevalence of upper respiratory tract infections, favourable drug pipeline, and rising demand for over-the-counter drugs. In addition, rising incidence and prevalence of upper respiratory tract infections is anticipated to boost the growth of the market as well.

The upper respiratory tract infection treatment market analysis includes type segment and geographic landscapes

Technavio's ‘ upper respiratory tract infection treatment market ’ is segmented as below:

By Type:

  • Antibiotics
  • NSAIDs and nasal decongestants
  • others

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the increasing R&D on upper respiratory tract infection treatment as one of the prime reasons driving the upper respiratory tract infection treatment market growth during the next few years. Also, emergence of biologics, and development of drug delivery devices to treat upper respiratory tract infections will lead to sizable demand in the market.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our upper respiratory tract infection treatment market covers the following areas:

  • Upper respiratory tract infection treatment market sizing
  • Upper respiratory tract infection treatment market forecast
  • Upper respiratory tract infection treatment market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading upper respiratory tract infection treatment market vendors that include AstraZeneca Plc, CSL Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.. Also, the upper respiratory tract infection treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Antibiotics - Market size and forecast 2019-2024
  • NSAIDs and nasal decongestants - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver - demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • CSL Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ billion)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Antibiotics - Market size and forecast 2019-2024 ($ billion)
  • 24: Antibiotics - Year-over-year growth 2019-2024 (%)
  • 25: NSAIDs and nasal decongestants - Market size and forecast 2019-2024 ($ billion)
  • 26: NSAIDs and nasal decongestants - Year-over-year growth 2019-2024 (%)
  • 27: Others - Market size and forecast 2019-2024 ($ billion)
  • 28: Others - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Type
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ billion)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ billion)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ billion)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ billion)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ billion)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: AstraZeneca Plc - Overview
  • 50: AstraZeneca Plc - Business segments
  • 51: AstraZeneca Plc - Key offerings
  • 52: AstraZeneca Plc - Key customers
  • 53: AstraZeneca Plc - Segment focus
  • 54: CSL Ltd. - Overview
  • 55: CSL Ltd. - Business segments
  • 56: CSL Ltd. - Key offerings
  • 57: CSL Ltd. - Key customers
  • 58: CSL Ltd. - Segment focus
  • 59: GlaxoSmithKline Plc - Overview
  • 60: GlaxoSmithKline Plc - Business segments
  • 61: GlaxoSmithKline Plc - Key offerings
  • 62: GlaxoSmithKline Plc - Key customers
  • 63: GlaxoSmithKline Plc - Segment focus
  • 64: Merck & Co. Inc. - Overview
  • 65: Merck & Co. Inc. - Business segments
  • 66: Merck & Co. Inc. - Key offerings
  • 67: Merck & Co. Inc. - Key customers
  • 68: Merck & Co. Inc. - Segment focus
  • 69: Novartis AG - Overview
  • 70: Novartis AG - Business segments
  • 71: Novartis AG - Key offerings
  • 72: Novartis AG - Key customers
  • 73: Novartis AG - Segment focus
  • 74: Pfizer Inc. - Overview
  • 75: Pfizer Inc. - Business segments
  • 76: Pfizer Inc. - Key offerings
  • 77: Pfizer Inc. - Key customers
  • 78: Pfizer Inc. - Segment focus
  • 79: Regeneron Pharmaceuticals Inc. - Overview
  • 80: Regeneron Pharmaceuticals Inc. - Business segments
  • 81: Regeneron Pharmaceuticals Inc. - Key offerings
  • 82: Regeneron Pharmaceuticals Inc. - Key customers
  • 83: Regeneron Pharmaceuticals Inc. - Segment focus
  • 84: Sanofi - Overview
  • 85: Sanofi - Business segments
  • 86: Sanofi - Key offerings
  • 87: Sanofi - Key customers
  • 88: Sanofi - Segment focus
  • 89: Teva Pharmaceutical Industries Ltd. - Overview
  • 90: Teva Pharmaceutical Industries Ltd. - Business segments
  • 91: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 92: Teva Pharmaceutical Industries Ltd. - Key customers
  • 93: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 94: Currency conversion rates for US$
  • 95: Research Methodology
  • 96: Validation techniques employed for market sizing
  • 97: Information sources
  • 98: List of abbreviations